HIV Treatment Bulletin - December 2003 / January 2004
Simon Collins, HIV i-Base

Although guidelines widely recommend use of efavirenz (EFV, Sustiva, Stocrin) plus two nucleosides for initial therapy a percentage of patients find the associated CNS side effects substantially reduces their quality of life.

Ward and colleagues from a private practice in Washington DC performed a retrospective review of 34 patients with undetectable viral load <50 copies/mL, and three patients with 50-1000 copies/mL, who switched from efavirenz to nevirapine due to CNS-related side effects or lipid problems. The two viral load tests prior to the switch were compared to most results in October 2003.

In the absence of data on the interaction between the two drugs, and the specific effect on the pharmacokinetic induction of metabolism, nevirapine was started at a dose of 200mg once-daily for two weeks, overlapping efavirenz therapy. Efavirenz was then stopped and nevirapine increased to the 200mg twice-daily dose.

All patients who were undetectable at the switch have remained <50 copies after a median of 25 months (range 6-59). Two of the intermittently detectable patients have remained between 50-1000 copies/mL and one has become persistently <50 copies/mL.

Patients who previously reported psychiatric problems (depression, anxiety or fatigue, with or without sleep disturbance) all resolved or significantly improved. Four patients with previous isolated sleep disturbance all had significant improvement in quality of sleep.

One patient, the only woman in the cohort, switched to nevirapine in order to become pregnant, had artificial insemination and delivered a healthy HIV-negative baby boy.

One patient had acute hepatic toxicity and changed to acabavir/AZT/3TC.

Ref: Ward DJ, Curtain JM. Substitution of nevirapine for efavirenz in virologically controlled patients intolerant of efavirenz. European AIDS Conf 2003 Oct 25-29;9:7.5/17 (Abstract no. 205).

031210
IB30410-04

©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.